Dyne Therapeutics, Inc.
DYNNasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — |
| Operating income | −$468.2M | −$343.9M | −$242.2M | −$171.0M | −$150.0M | −$58.6M |
| Net income | −$446.2M | −$317.4M | −$235.9M | −$168.1M | −$149.3M | −$59.4M |
| Total assets | $1.19B | $691.2M | $165.1M | $306.3M | $425.7M | $353.3M |
| Total liabilities | $214.8M | $61.4M | $73.8M | $54.0M | $57.5M | $11.0M |
| Equity | $972.1M | $629.8M | $91.3M | $252.4M | $368.2M | $342.4M |
| EPS (diluted) | $-3.47 | $-3.37 | $-3.95 | $-3.23 | $-2.93 | — |
| Shares out. | 113.1M | 82.0M | 56.3M | 51.6M | 51.5M | 45.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- −45.9%
- Return on assets
- −37.6%
- Return on capital (ROCE)
- −41.2%
- Liabilities / assets
- 18.1%
- Debt / equity
- 0.22×
- Book value / share
- $8.59
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 4.21safe
- Accruals / assets
- −3.6%clean
- Piotroski F-Score
- 3/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 1 warning● 3 good- Negative operating cash flow
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 3Recruitingreadout ~2028-07Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1
- Phase 1/2Recruitingreadout ~2029-07Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
- Phase 1/2Active Not Recruitingreadout ~2029-11Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-251 in Participants With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
- Phase 3Recruitingreadout ~2030-12Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- T. Rowe Price Investment Management, Inc.Passive (13G)May 15, 2026
- Janus Henderson Group PlcPassive (13G)May 15, 2026
- Fmr LlcPassive (13G)May 6, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Ra Capital Management, L.P.Passive (13G)Nov 14, 2025
- Atlas Venture Fund Xi, L.P.Passive (13G)Nov 13, 2025
- Forbion Capital Fund Iv Cooperatief U.A.Passive (13G)May 15, 2025
- Rtw Investments, LpPassive (13G)May 15, 2025
- Point72 Asset Management, L.P.Passive (13G)May 15, 2025
- Blackrock, Inc.Passive (13G)Apr 17, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 21.0M | 16.8 | +1.2% |
| Apr 30, 2026 | 20.7M | 11.4 | -4.5% |
| Apr 15, 2026 | 21.7M | 13.4 | +6.0% |
| Mar 31, 2026 | 20.5M | 8.4 | +7.1% |
| Mar 13, 2026 | 19.1M | 6.6 | -1.1% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Results of operationsMay 11, 2026
- Results of operationsMar 2, 2026
- Results of operations · Regulation FD disclosureJan 12, 2026
- Director / officer changeDec 23, 2025
- Entered a material agreement · Other material eventDec 10, 2025
- New financial obligationDec 8, 2025
- Regulation FD disclosure · Other material eventDec 8, 2025
- Results of operationsNov 5, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.